Kaplan Fox & Kilsheimer LLP announced that a securities class action has been filed against Beta Bionics, Inc. (Nasdaq: BBNX) on behalf of investors who purchased or acquired the company’s common stock from July 30, 2025, through February 24, 2026. The case, Holtzman v. Beta Bionics, Inc. et al., is pending in the United States District Court for the Central District of California under docket number 26-cv-02612. Investors have until November 3, 2026, to ask the court to appoint them as lead plaintiff, although participation as lead plaintiff is not required to share in any recovery. The complaint alleges that Beta Bionics concealed thousands of customer complaints involving its iLet Bionic Pancreas insulin pump, including serious hypoglycemia incidents allegedly caused by an aggressive automated dosing algorithm. It further alleges that the company failed to investigate or report incidents properly to the U.S. Food and Drug Administration. Investors were allegedly alerted by a January 8, 2026, miss on new iLet patient starts, followed by a 37% one-day share-price decline, and by an FDA warning letter that the release says was publicly issued on February 24. Earlier case materials said a June 2025 FDA Form 483 identified more than 18,000 unreported complaints and that the company’s shares fell from $31.99 on January 8 to below $9 by April 10. The allegations have not been adjudicated.